SEARCH

SEARCH BY CITATION

References

  • Artz, A.S., Van Besien, K., Zimmerman, T., Gajewski, T.F., Rini, B.I., Hu, H.S., Stadler, W.M. & Vogelzang, N.J. (2005) Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplantation, 35, 253260.
  • Baron, F., Frere, P., Baudoux, E., Sautois, B., Fillet, G. & Beguin, Y. (2003) Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. Haematologica, 88, 479480.
  • Blaise, D., Bay, J.O., Faucher, C., Michallet, M., Boiron, J.M., Choufi, B., Cahn, J.Y., Gratecos, N., Sotto, J.J., Francois, S., Fleury, J., Mohty, M., Chabannon, C., Bilger, K., Gravis, G., Viret, F., Braud, A.C., Bardou, V.J., Maraninchi, D. & Viens, P. (2004) Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood, 103, 435441.
  • Bregni, M., Dodero, A., Peccatori, J., Pescarollo, A., Bernardi, M., Sassi, I., Voena, C., Zaniboni, A., Bordignon, C. & Corradini, P. (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood, 99, 42344236.
  • Castagna, L., Bertuzzi, A., Nozza, A., Siracusano, L., Balzarotti, M., Magagnoli, M., Sarina, B., Timofeeva, I., Sinnone, M., Grimoldi, M.G., Fare, M. & Santoro, A. (2002) Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas. Bone Marrow Transplantation, 30, 207214.
  • Childs, R. & Srinivasan, R. (2002) Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer Journal, 8, 211.
  • Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E.J., Tisdale, J., Dunbar, C., Linehan, W.M., Young, N.S. & Barrett, A.J. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New England Journal of Medicine, 343, 750758.
  • Citterio, G., Bertuzzi, A., Tresoldi, M., Galli, L., Di Lucca, G., Scaglietti, U. & Rugarli, C. (1997) Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. European Urology, 31, 286291.
  • Cochran, W.G. (1954) Some methods for strengthening the common chi-square tests. Biometrics, 10, 417451.
  • Fisher, R.I., Rosenberg, S.A., Sznol, M., Parkinson, D.R. & Fyfe, G. (1997) High-dose aldesleukin in renal cell carcinoma: long-term survival update. The Cancer Journal from Scientific American, 3(Suppl 1), 7072.
  • Hentschke, P., Barkholt, L., Uzunel, M., Mattsson, J., Wersall, P., Pisa, P., Martola, J., Albiin, N., Wernerson, A., Soderberg, M., Remberger, M., Thorne, A. & Ringden, O. (2003) Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplantation, 31, 253261.
  • Huugen, D., Bos, G.M., Jansen, M., Lalisang, R., Jansen, R., Wagstaff, J. & Schouten, H.C. (2002) Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy. Netherlands Journal of Medicine, 60, 170173.
  • Javidan, J., Stricker, H.J., Tamboli, P., Amin, M.B., Peabody, J.O., Deshpande, A. & Menon, M. (1999) Prognostic significance of the 1997 TNM classification of renal cell carcinoma. Journal of Urology, 162, 12771281.
  • Jemal, A., Tiwari, R.C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E.J. & Thun, M.J. (2004) Cancer statistics, 2004*. CA: A Cancer Journal for Clinicians, 54, 829.
  • Kalish, L.A. & Begg, C.B. (1987) The impact of treatment allocation procedures on nominal significance levels and bias. Controlled Clinical Trials, 8, 121135.
  • Karrison, T.G., Huo, D. & Chappell, R. (2003) A group sequential, response-adaptive design for randomized clinical trials. Controlled Clinical Trials, 24, 506522.
  • Ljungberg, B., Landberg, G. & Alamdari, F.I. (2000) Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scandinavian Journal of Urology and Nephrology, 34, 246251.
  • Massenkeil, G., Roigas, J., Nagy, M., Wille, A., Stroszczynski, C., Mapara, M.Y., Loening, S., Dorken, B. & Arnold, R. (2004) Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplantation, 34, 309316.
  • Mejean, A., Hopirtean, V., Bazin, J.P., Larousserie, F., Benoit, H., Chretien, Y., Thiounn, N. & Dufour, B. (2003) Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. Journal of Urology, 170, 764767.
  • Motzer, R.J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A. & Ferrara, J. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of Clinical Oncology, 17, 25302540.
  • Motzer, R.J., Bacik, J., Schwartz, L.H., Reuter, V., Russo, P., Marion, S. & Mazumdar, M. (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 22, 454463.
  • Naito, S., Kimiya, K., Sakamoto, N., Soejima, T., Ueda, T., Kumazawa, J., Osada, Y., Kurozumi, T., Sagiyama, K. & Ariyoshi, A. (1991) Prognostic factors and value of adjunctive nephrectomy in patients with stage IV renal cell carcinoma. Urology, 37, 9599.
  • Nakagawa, T., Kami, M., Hori, A., Kim, S.W., Murashige, N., Hamaki, T., Kishi, Y., Fujimoto, H., Matsuoka, N., Okajima, E., Komiyama, M., Tobisu, K., Wakayama, T., Uike, N., Tajima, K., Makimoto, A., Mori, S., Tanosaki, R., Takaue, Y. & Kakizoe, T. (2004) Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Experimental Hematology, 32, 599606.
  • Pedrazzoli, P., Da Prada, G.A., Giorgiani, G., Schiavo, R., Zambelli, A., Giraldi, E., Landonio, G., Locatelli, F., Siena, S. & Della Cuna, G.R. (2002) Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer, 94, 24092415.
  • Rini, B.I., Zimmerman, T., Stadler, W.M., Gajewski, T.F. & Vogelzang, N.J. (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. Journal of Clinical Oncology, 20, 20172024.
  • Rosenberg, S.A., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H. & White, D.E. (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. The Journal of the American Medical Association, 271, 907913.
  • Therneau, T. & Grambsch, P. (2000) Modeling Survival Data: Extending the Cox Model. Springer-Verlag Inc., Berlin, New York.
  • Tsui, K.H., Shvarts, O., Smith, R.B., Figlin, R.A., de Kernion, J.B. & Belldegrun, A. (2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. Journal of Urology, 163, 10901095; quiz 1295.
  • Tykodi, S.S., Warren, E.H., Thompson, J.A., Riddell, S.R., Childs, R.W., Otterud, B.E., Leppert, M.F., Storb, R. & Sandmaier, B.M. (2004) Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clinical Cancer Research, 10, 77997811.
  • Ueno, N.T., Cheng, Y.C., Rondon, G., Tannir, N.M., Gajewski, J.L., Couriel, D.R., Hosing, C., De Lima, M.J., Anderlini, P., Khouri, I.F., Booser, D.J., Hortobagyi, G.N., Pagliaro, L.C., Giralt, S.A. & Champlin, R.E. (2003) Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem-cell transplantation for metastatic solid tumors. Blood, 102, 38293836.